Multivariate analyses: effect of HLA-DPB1 ΔFD or TCE matching status and other non-HLA variables on clinical outcome
| Outcome and variable . | N* . | HR . | 95% CI . | P† . |
|---|---|---|---|---|
| OS | ||||
| HLA-DPB1 ΔFD | 132 (52) / 49 (39) | 1.40 | 1.05-1.87 | <.021 |
| HLA-DPB1 TCE | 103 (51) / 78 (44) | 1.15 | 0.86-1.54 | <.360 |
| Number of HLA-DPB1 allele mismatches | 120 (47) / 61 (48) | 0.97 | 0.71-1.32 | <.830 |
| Recipient age | 102 (54) / 79 (42) | 1.69 | 1.26-2.27 | <.0006 |
| Disease status at transplant | 96 (58) / 44 (49) / 41 (33) | 1.30 | 1.10-1.55 | <.003 |
| In vivo T-cell depletion (ATG) | 69 (37) / 112 (59) | 0.56 | 0.41-0.76 | <.0003 |
| EFS | ||||
| HLA-DPB1 ΔFD | 119 (47) / 43 (34) | 1.39 | 1.05-1.82 | <.021 |
| HLA-DPB1 TCE | 92 (45) / 70 (40) | 1.09 | 0.84-1.43 | <.510 |
| Number of HLA-DPB1 allele mismatches | 105 (42) / 57 (45) | 0.92 | 0.68-1.25 | <.588 |
| Recipient age | 93 (49) / 69 (36) | 1.59 | 1.20-2.10 | <.002 |
| Disease status at transplant | 84 (51) / 41 (46) / 37 (30) | 1.24 | 1.05-1.46 | <.010 |
| In vivo T-cell depletion (ATG) | 65 (35) / 97 (51) | 0.65 | 0.49-0.87 | <.004 |
| Relapse | ||||
| HLA-DPB1 ΔFD | 67 (27) / 41 (32) | 1.69 | 0.99-2.87 | <.055 |
| HLA-DPB1 TCE | 57 (28) / 51 (29) | 0.75 | 0.45-1.24 | <.261 |
| Number of HLA-DPB1 allele mismatches | 72 (28) / 36 (29) | 0.97 | 0.63-1.49 | <.901 |
| Recipient age | 54 (29) / 54 (28) | 1.33 | 0.88-2.01 | <.178 |
| Disease status at transplant | 49 (30) / 20 (22) / 39 (31) | 1.15 | 0.90-1.46 | <.255 |
| In vivo T-cell depletion (ATG) | 55 (29) / 53 (28) | 0.85 | 0.56-1.27 | <.422 |
| NRM | ||||
| HLA-DPB1 ΔFD | 67 (27) / 42 (33) | 1.48 | 0.88-2.51 | <.143 |
| HLA-DPB1 TCE | 54 (27) / 55 (31) | 0.98 | 0.59-1.61 | <.931 |
| Number of HLA-DPB1 allele mismatches | 76 (30) / 33 (26) | 0.81 | 0.53-1.26 | <.366 |
| Recipient age | 42 (22) / 67 (35) | 2.13 | 1.40-3.24 | <.0005 |
| Disease status at transplant | 34 (20) / 27 (30) / 48 (39) | 1.34 | 1.06-1.69 | <.016 |
| In vivo T-cell depletion (ATG) | 68 (36) / 41 (21) | 0.52 | 0.34-0.78 | <.002 |
| Acute GVHD grades II-IV | ||||
| HLA-DPB1 ΔFD | 96 (38) / 44 (35) | 0.99 | 0.63-1.57 | <.985 |
| HLA-DPB1 TCE | 80 (39) / 60 (34) | 0.82 | 0.53-1.27 | <.382 |
| Number of HLA-DPB1 allele mismatches | 93 (37) / 47 (37) | 1.08 | 0.74-1.58 | <.684 |
| Recipient age | 73 (39) / 67 (35) | 0.78 | 0.54-1.10 | <.158 |
| Disease status at transplant | 55 (33) / 32 (36) / 53 (43) | 1.10 | 0.90-1.36 | <.354 |
| In vivo T-cell depletion (ATG) | 74 (39) / 66 (34) | 0.91 | 0.63-1.33 | <.634 |
| Acute GVHD grades III-IV | ||||
| HLA-DPB1 ΔFD | 37 (15) / 18 (14) | 0.98 | 0.48-2.01 | <.967 |
| HLA-DPB1 TCE | 30 (15) / 25 (14) | 1.00 | 0.51-1.99 | <.993 |
| Number of HLA-DPB1 allele mismatches | 38 (15) / 17 (13) | 0.88 | 0.47-1.64 | <.691 |
| Recipient age | 28 (15) / 27 (14) | 1.02 | 0.58-1.79 | <.954 |
| Disease status at transplant | 21 (13) / 8 (9) / 26 (21) | 1.19 | 0.85-1.68 | <.304 |
| In vivo T-cell depletion (ATG) | 35 (19) / 20 (10) | 0.59 | 0.33-1.01 | <.090 |
| Chronic GVHD | ||||
| HLA-DPB1 ΔFD | 118 (47) / 67 (53) | 0.81 | 0.56-1.20 | <.282 |
| HLA-DPB1 TCE | 86 (42) / 99 (56) | 1.42 | 1.01-1.90 | <.016 |
| Number of HLA-DPB1 allele mismatches | 119 (47) / 66 (52) | 1.08 | 0.78-1.49 | <.656 |
| Recipient age | 96 (51) / 89 (47) | 0.86 | 0.63-1.18 | <.349 |
| Disease status at transplant | 82 (50) / 49 (55) / 54 (44) | 0.90 | 0.75-1.09 | <.278 |
| In vivo T-cell depletion (ATG) | 95 (51) / 90 (47) | 0.71 | 0.53-0.95 | <.021 |
| Outcome and variable . | N* . | HR . | 95% CI . | P† . |
|---|---|---|---|---|
| OS | ||||
| HLA-DPB1 ΔFD | 132 (52) / 49 (39) | 1.40 | 1.05-1.87 | <.021 |
| HLA-DPB1 TCE | 103 (51) / 78 (44) | 1.15 | 0.86-1.54 | <.360 |
| Number of HLA-DPB1 allele mismatches | 120 (47) / 61 (48) | 0.97 | 0.71-1.32 | <.830 |
| Recipient age | 102 (54) / 79 (42) | 1.69 | 1.26-2.27 | <.0006 |
| Disease status at transplant | 96 (58) / 44 (49) / 41 (33) | 1.30 | 1.10-1.55 | <.003 |
| In vivo T-cell depletion (ATG) | 69 (37) / 112 (59) | 0.56 | 0.41-0.76 | <.0003 |
| EFS | ||||
| HLA-DPB1 ΔFD | 119 (47) / 43 (34) | 1.39 | 1.05-1.82 | <.021 |
| HLA-DPB1 TCE | 92 (45) / 70 (40) | 1.09 | 0.84-1.43 | <.510 |
| Number of HLA-DPB1 allele mismatches | 105 (42) / 57 (45) | 0.92 | 0.68-1.25 | <.588 |
| Recipient age | 93 (49) / 69 (36) | 1.59 | 1.20-2.10 | <.002 |
| Disease status at transplant | 84 (51) / 41 (46) / 37 (30) | 1.24 | 1.05-1.46 | <.010 |
| In vivo T-cell depletion (ATG) | 65 (35) / 97 (51) | 0.65 | 0.49-0.87 | <.004 |
| Relapse | ||||
| HLA-DPB1 ΔFD | 67 (27) / 41 (32) | 1.69 | 0.99-2.87 | <.055 |
| HLA-DPB1 TCE | 57 (28) / 51 (29) | 0.75 | 0.45-1.24 | <.261 |
| Number of HLA-DPB1 allele mismatches | 72 (28) / 36 (29) | 0.97 | 0.63-1.49 | <.901 |
| Recipient age | 54 (29) / 54 (28) | 1.33 | 0.88-2.01 | <.178 |
| Disease status at transplant | 49 (30) / 20 (22) / 39 (31) | 1.15 | 0.90-1.46 | <.255 |
| In vivo T-cell depletion (ATG) | 55 (29) / 53 (28) | 0.85 | 0.56-1.27 | <.422 |
| NRM | ||||
| HLA-DPB1 ΔFD | 67 (27) / 42 (33) | 1.48 | 0.88-2.51 | <.143 |
| HLA-DPB1 TCE | 54 (27) / 55 (31) | 0.98 | 0.59-1.61 | <.931 |
| Number of HLA-DPB1 allele mismatches | 76 (30) / 33 (26) | 0.81 | 0.53-1.26 | <.366 |
| Recipient age | 42 (22) / 67 (35) | 2.13 | 1.40-3.24 | <.0005 |
| Disease status at transplant | 34 (20) / 27 (30) / 48 (39) | 1.34 | 1.06-1.69 | <.016 |
| In vivo T-cell depletion (ATG) | 68 (36) / 41 (21) | 0.52 | 0.34-0.78 | <.002 |
| Acute GVHD grades II-IV | ||||
| HLA-DPB1 ΔFD | 96 (38) / 44 (35) | 0.99 | 0.63-1.57 | <.985 |
| HLA-DPB1 TCE | 80 (39) / 60 (34) | 0.82 | 0.53-1.27 | <.382 |
| Number of HLA-DPB1 allele mismatches | 93 (37) / 47 (37) | 1.08 | 0.74-1.58 | <.684 |
| Recipient age | 73 (39) / 67 (35) | 0.78 | 0.54-1.10 | <.158 |
| Disease status at transplant | 55 (33) / 32 (36) / 53 (43) | 1.10 | 0.90-1.36 | <.354 |
| In vivo T-cell depletion (ATG) | 74 (39) / 66 (34) | 0.91 | 0.63-1.33 | <.634 |
| Acute GVHD grades III-IV | ||||
| HLA-DPB1 ΔFD | 37 (15) / 18 (14) | 0.98 | 0.48-2.01 | <.967 |
| HLA-DPB1 TCE | 30 (15) / 25 (14) | 1.00 | 0.51-1.99 | <.993 |
| Number of HLA-DPB1 allele mismatches | 38 (15) / 17 (13) | 0.88 | 0.47-1.64 | <.691 |
| Recipient age | 28 (15) / 27 (14) | 1.02 | 0.58-1.79 | <.954 |
| Disease status at transplant | 21 (13) / 8 (9) / 26 (21) | 1.19 | 0.85-1.68 | <.304 |
| In vivo T-cell depletion (ATG) | 35 (19) / 20 (10) | 0.59 | 0.33-1.01 | <.090 |
| Chronic GVHD | ||||
| HLA-DPB1 ΔFD | 118 (47) / 67 (53) | 0.81 | 0.56-1.20 | <.282 |
| HLA-DPB1 TCE | 86 (42) / 99 (56) | 1.42 | 1.01-1.90 | <.016 |
| Number of HLA-DPB1 allele mismatches | 119 (47) / 66 (52) | 1.08 | 0.78-1.49 | <.656 |
| Recipient age | 96 (51) / 89 (47) | 0.86 | 0.63-1.18 | <.349 |
| Disease status at transplant | 82 (50) / 49 (55) / 54 (44) | 0.90 | 0.75-1.09 | <.278 |
| In vivo T-cell depletion (ATG) | 95 (51) / 90 (47) | 0.71 | 0.53-0.95 | <.021 |
ΔFD, δ-functional distance.
Numbers (N) refer to the number of censored patients (% total) for OS and EFS, and the number of events (% total) for the other end points, in the reference group before the slash vs the group of interest after the slash, as follows: HLA-DPB1 ΔFD ≤2.665 / >2.665; HLA-DPB1 TCE permissive/nonpermissive; number of HLA-DPB1 allele mismatches one/two; recipient age < median / > median (53 y); disease status at transplant early/intermediate/advanced; in vivo T-cell depletion (ATG) No/Yes. The total number of patients in each reference group before the slash vs the group of interest after the slash were as follows: HLA-DPB1 ΔFD 252/127; HLA-DPB1 TCE 203/176; number of HLA-DPB1 allele mismatches 253/126; recipient age 189/190; disease status at transplant 166/89/124; in vivo T-cell depletion (ATG) 188/191.
Proportional hazards P value.